Seeking Alpha

OTCShowcase's  Instablog

OTCShowcase
Send Message
I am a long and short term trader that has been involved with the stock market for many years. Primarily a technical analyst to trade, I enjoy diving into the microcap stock world looking for hidden gems. I am looking for companies that meet a select criteria of strong management, products... More
  • Taglich Updates ALR Technologies (ALRT), Maintains 50 Cent Price Target 0 comments
    May 24, 2012 9:07 AM | about stocks: ALRT

    Taglich Updates ALR Technologies, Maintains 50 Cent Price Target

    Analyst firm Taglich Brothers has updated their research report on ALR Technologies (OTCBB: ALRT). The New York-based firm has maintained their 50 cent, 12-month price target on ALRT and "Speculative Buy" rating based on five-year revenue potential for the company. Shares of ALRT closed trading on Wednesday at $0.0795; ahead 13.57% from Tuesday's closing price.

    The research update can be viewed here.

    ALR Technologies Inc., based in Richmond, Virginia, has developed Heatlh-e-Connect (HeC), an FDA-cleared Internet-based system that links patients and clinicians. HeC records and transmits diagnostic data, e.g., self-monitored blood glucose data collected by patients, which can be uploaded to a personal computer and transmitted over the Internet to clinicians. The data is reviewed by clinicians who can communicate over HeC to patients or their caregivers. HeC is useful for managing patients with diabetes and other chronic diseases that lend themselves to self-monitoring, and for recording usage of self-monitoring test supplies. Data collected by HeC can also enable health insurers to monitor patient compliance by accurately tracking their consumption.

    ------------------------------

    Disclaimer: Neither www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters ("us" or "we") is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has been compensated three thousand dollars for one month of consultation and journalism services and to manage an investor relations/awareness program by ALR Technologies. Viper has completed prior service agreements with ALRT Technologies with full disclosure listed on our disclaimer/disclosure page. Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.

Back To OTCShowcase's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

  • Momenta Pharmaceuticals (MNTA) & Sadoz (unit of NVS) - Judge Emmet Sullivan refuses injunction to stop generic of Sanofi-Aventis' Lovenox.
    Aug 26, 2010
  • Daytrade: GNVC. Long term: investing Cellceutix real heavy. I'm loving them as a long-term play from everything I see.
    Mar 30, 2010
More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.